Badr Eslam Roza, Siostrzonek Peter, Eber Bernd, Podczeck-Schweighofer Andrea, Lang Irene
Univ.-Klinik für Innere Medizin II, Abteilung für Kardiologie, Wien, Austria.
Wien Klin Wochenschr. 2010 Aug;122(15-16):486-93. doi: 10.1007/s00508-010-1419-9. Epub 2010 Aug 6.
Based on the evidence from large clinical and epidemiological studies indicating an independent prognostic role of heart rate in cardiovascular disease, the assessment and correction of elevated heart rate is of significant prognostic relevance. In the present study conducted with the support of 74 specialists of Internal Medicine in 2009 in Austria, heart rate in patients with coronary heart disease (CHD) and chronic stable angina pectoris was evaluated in relation to pre-existing and concomitant diseases, angina-severity (CCS), angina-symptoms and treatment. For all variables, descriptive statistical analyses were performed according to three predefined groups with heart rates <60 bpm (HR-1), 60-70 bpm (HR-2), and >70 bpm (HR-3). Of the 1280 patients 21.8% had a heart rate of <60 bpm, 39.6% of 60-70 bpm, and 38.5% of >70 bpm. A significant association was shown between elevated heart rate and concomitant disease, e.g., peripheral artery disease (p = 0.046), psoriasis (p = 0.029), previous acute coronary syndrome (p = 0.001), COPD (p < 0.001), diabetes mellitus (p = 0.004), and depression (p < 0.001). CCS-severity was correlated with heart rates (mean values; CCS-0: 66.8 bpm, CCS-IV: 77.5 bpm). Angina-pectoris (AP) symptoms were more common in patients with heart rates of >70 bpm (HR-3: 1,2 AP-events/week; HR-2: 1 AP-events/week; HR-1: 0,7 AP events/week; each time p < 0.001). The majority of patients were treated with betablockers (74%); yet, the average dose was approximately half the maximal recommended dose. Despite inadequate heart rate reduction in patients on betablockers, selective heart rate lowering agents such as ivabradine were used in only 1.6% of patients. Overall, these results illustrate that heart rate as an important therapeutic target in CHD-patients with chronic stable angina is still underestimated in contemporary clinical practice.
基于大型临床和流行病学研究的证据表明心率在心血管疾病中具有独立的预后作用,因此评估和纠正心率升高具有重要的预后意义。在2009年奥地利74位内科专家支持下开展的本研究中,对冠心病(CHD)和慢性稳定性心绞痛患者的心率与既往疾病和伴随疾病、心绞痛严重程度(加拿大心血管学会分级,CCS)、心绞痛症状及治疗情况进行了评估。对于所有变量,根据心率<60次/分钟(HR-1)、60-70次/分钟(HR-2)和>70次/分钟(HR-3)这三个预定义组进行描述性统计分析。在1280例患者中,21.8%的患者心率<60次/分钟,39.6%的患者心率为60-70次/分钟,38.5%的患者心率>70次/分钟。心率升高与伴随疾病之间存在显著关联,例如外周动脉疾病(p = 0.046)、银屑病(p = 0.029)、既往急性冠脉综合征(p = 0.001)、慢性阻塞性肺疾病(p < 0.001)、糖尿病(p = 0.004)和抑郁症(p < 0.001)。CCS严重程度与心率相关(平均值;CCS-0:66.8次/分钟,CCS-IV:77.5次/分钟)。心率>70次/分钟的患者心绞痛(AP)症状更为常见(HR-3:每周1.2次AP发作;HR-2:每周1次AP发作;HR-1:每周0.7次AP发作;每次p < 0.001)。大多数患者接受β受体阻滞剂治疗(74%);然而,平均剂量约为最大推荐剂量的一半。尽管使用β受体阻滞剂的患者心率降低不充分,但仅1.6%的患者使用了如伊伐布雷定等选择性心率降低药物。总体而言,这些结果表明,在当代临床实践中,心率作为慢性稳定性心绞痛CHD患者的重要治疗靶点仍被低估。